Last 1,220 KRW
Change Today +40.00 / 3.39%
Volume 7.0M
As of 2:29 AM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

geneonelifescience inc (011000) Snapshot

Open
1,210
Previous Close
1,180
Day High
1,250
Day Low
1,165
52 Week High
08/8/14 - 1,583
52 Week Low
06/27/14 - 838.50
Market Cap
70.2B
Average Volume 10 Days
7.7M
EPS TTM
-157.00
Shares Outstanding
57.5M
EX-Date
03/16/07
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENEONELIFESCIENCE INC (011000)

Related News

No related news articles were found.

geneonelifescience inc (011000) Related Businessweek News

No Related Businessweek News Found

geneonelifescience inc (011000) Details

GeneOne Life Science Inc., a biopharmaceutical company, researches and develops DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. Its products include VGX-3400, a DNA vaccine, which is in Phase I clinical trials for the prevention of avian influenza; VGX-3500, a prophylactic pre-pandemic influenza DNA vaccine, is in Phase I clinical trials that protects against swine, avian, and seasonal influenza; and FLUPRIME, a trivalent influenza vaccine, which is in Phase I clinical trials that prevents the outbreak of seasonal flu. The company is also developing VGX-6150, a therapeutic DNA vaccine that is in pre-clinical trials for the treatment of hepatitis C; and VGX-6200, a therapeutic DNA vaccine, which is under pre-clinical trials for the treatment of hepatitis B. In addition, it is involved in the contract manufacturing activities for pre-clinical and clinical trials for companies and institutions. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science Inc. in April 2014. GeneOne Life Science Inc. is headquartered in Seoul, South Korea.

geneonelifescience inc (011000) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

geneonelifescience inc (011000) Key Developments

Inovio Pharmaceuticals, Inc. Announces Phase I Clinical Trial for Ebola in Collaboration with GeneOne Life Science Inc

Inovio Pharmaceuticals, Inc. announced it will advance its DNA vaccine for Ebola into a phase I clinical trial in a collaboration with GeneOne Life Science Inc. In the collaboration Inovio and GeneOne will co-develop Inovio's DNA-based Ebola vaccine through a phase I clinical trial. The companies are currently conducting pre-IND activities and plan to start the clinical study in the first half of 2015. Upon successful completion of the phase I, the companies will jointly seek additional third party support and resources to further develop and commercialize this product. Along with the escalating spread of Ebola and related deaths, this virus is also mutating into diverse strains. There are no preventive vaccines or effective therapeutic approaches to Ebola; the ease with which Ebola is generating genetic variations will complicate the process of creating such solutions. In addition, various experimental approaches have already been associated with undesirable side effects and limited ability to scale manufacturing. Inovio's SynCon(R) technology has been the basis for immunotherapy and vaccine products which have demonstrated the ability to activate immune responses against multiple disease-specific antigens and elicit broad protection against diverse unmatched strains of pathogens in humans. These DNA-based immunotherapy products have demonstrated a very favorable safety profile. Furthermore, these synthetic immunotherapies are manufactured using established production processes. Inovio's Ebola vaccine was designed using the SynCon technology to provide broad protective antibody and T-cell responses against multiple strains of Ebola virus. In published preclinical testing of its Ebola vaccine, Inovio observed that 100% of vaccinated guinea pigs and mice were protected from death after being exposed to the Ebola virus. Unlike the non-vaccinated animals, vaccinated animals were also protected from weight loss, a measure of morbidity. Researchers found significant increases in neutralizing antibody titers and strong and broad levels of vaccine-induced T-cells, including "killer" T-cells, suggesting that this product could provide both preventive and treatment benefits.

VGX International Inc. to Consider Changes to Articles of Incorporation

VGX International Inc. will consider some changes to Articles of Incorporation at the Annual Meeting to be held on March 27, 2014.

VGX International Inc., Annual General Meeting, Mar 27, 2014

VGX International Inc., Annual General Meeting, Mar 27, 2014., at 09:00 Korea Standard Time. Location: Teheran-ro, Gangnam-gu. Agenda: To consider audit reports, sales reports, financial statements; to consider articles of incorporation some changes; to consider approval of the grant of stock options; to consider election of Directors; and to consider appointment of Audit.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
011000:KS 1,220.00 KRW +40.00

011000 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 011000.
View Industry Companies
 

Industry Analysis

011000

Industry Average

Valuation 011000 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENEONELIFESCIENCE INC, please visit www.vgxi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.